Coming soon – June 2019 Over the past two decades, in response to mounting...
Coming soon – June 2019 Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies...
Coming Soon – July 2019 Given the seemingly constant failure of emerging...
Coming Soon – July 2019 Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid...
For the estimated 3.4 million people in the United States who suffer from...
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved pharmacotherapy is limited to four proc...
The Alzheimer’s disease (AD) market today comprises a handful of symptomatic...
The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving am...
For the estimated 3.4 million people in the United States who suffer from...
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive symptom......
DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises...
DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of...
Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely...
Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages...
The market for Alzheimer’s disease (AD) pharmacotherapies represents an...
The market for Alzheimer’s disease (AD) pharmacotherapies represents an enormous commercial opportunity driven by considerable unmet......
There is increased industry focus on the behavioral symptoms of Alzheimer’s...
There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason....
For the estimated 3 million people in the United States who have Alzheimer’s...
For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive symptomatic therapies (e.g., donepezil, memantine) that......
The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous...
The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is poised to grow r......
Although the Alzheimer’s disease (AD) treatment paradigm is stable and most...
Although the Alzheimer’s disease (AD) treatment paradigm is stable and most current treatments in the United States are generically available, several new therapies for AD, including the fi...
With a growing population and an enormous clinical need for improved...
With a growing population and an enormous clinical need for improved treatments, the market for Alzheimer’s disease (AD) pharmacotherapies represents a massive commercial opportunity that c...
With no significant drug launches occurring in more than a decade, the...
With no significant drug launches occurring in more than a decade, the overarching treatment paradigms in Alzheimer’s disease (AD) are mostly stable. However, understanding what factors and...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
Introduction Alzheimer’s disease is a chronic disease than affects several...
Introduction Alzheimer’s disease is a chronic disease than affects several million Brazilian and Mexican patients. Physicians have a small number of molecules avai...
